In addition, we demonstrate that NXP800 reduces HSP72 expression and decreases AR signaling, reduces AR and AR-V7 protein expression as well as their DNA binding and transactivation, and also inhibits the growth of treatment-resistant prostate cancer models. The gene discussed is AR; the disease is prostate carcinoma.